Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

BACKGROUND: The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood pressure in patients with type 2 diabetes through 52 weeks of treatment. In this rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Kristin, Gurney, Kate, Han, Jenny, Pencek, Richard, Walsh, Brandon, Trautmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112417/
https://www.ncbi.nlm.nih.gov/pubmed/21529363
http://dx.doi.org/10.1186/1472-6823-11-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112417/
https://www.ncbi.nlm.nih.gov/pubmed/21529363
http://dx.doi.org/10.1186/1472-6823-11-9

Ejemplares similares